RAD17 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| FC, WB, E |
---|---|
Primary Accession | O75943 |
Other Accession | NP_579916.1, NP_002864.1, NP_579917.1, NP_579918.1, NP_579922.1, NP_579920.1, NP_579919.1, N |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 77055 Da |
Antigen Region | 218-246 aa |
Gene ID | 5884 |
---|---|
Other Names | Cell cycle checkpoint protein RAD17, hRad17, RF-C/activator 1 homolog, RAD17, R24L |
Target/Specificity | This RAD17 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 218-246 amino acids from the Central region of human RAD17. |
Dilution | WB~~1:1000 FC~~1:10~50 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | RAD17 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | RAD17 {ECO:0000303|PubMed:9878245, ECO:0000312|HGNC:HGNC:9807} |
---|---|
Function | Essential for sustained cell growth, maintenance of chromosomal stability, and ATR-dependent checkpoint activation upon DNA damage (PubMed:10208430, PubMed:11418864, PubMed:11687627, PubMed:11799063, PubMed:12672690, PubMed:14624239, PubMed:15235112). Has a weak ATPase activity required for binding to chromatin (PubMed:10208430, PubMed:11418864, PubMed:11687627, PubMed:11799063, PubMed:12672690, PubMed:14624239, PubMed:15235112). Participates in the recruitment of the 9-1-1 (RAD1-RAD9-HUS1) complex and RHNO1 onto chromatin, and in CHEK1 activation (PubMed:21659603). May also serve as a sensor of DNA replication progression, and may be involved in homologous recombination (PubMed:14500819, PubMed:12578958, PubMed:15538388). |
Cellular Location | Nucleus. Note=Phosphorylated form redistributes to discrete nuclear foci upon DNA damage. |
Tissue Location | Overexpressed in various cancer cell lines and in colon carcinoma (at protein level). Isoform 2 and isoform 3 are the most abundant isoforms in non irradiated cells (at protein level) Ubiquitous at low levels. Highly expressed in testis, where it is expressed within the germinal epithelium of the seminiferous tubuli Weakly expressed in seminomas (testicular tumors) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is highly similar to the gene product of Schizosaccharomyces pombe rad17, a cell cycle checkpoint gene required for cell cycle arrest and DNA damage repair in response to DNA damage. This protein shares strong similarity with DNA replication factor C (RFC), and can form a complex with RFCs. This protein binds to chromatin prior to DNA damage and is phosphorylated by the checkpoint kinase ATR following damage. This protein recruits the RAD1-RAD9-HUS1 checkpoint protein complex onto chromatin after DNA damage, which may be required for its phosphorylation. The phosphorylation of this protein is required for the DNA-damage-induced cell cycle G2 arrest, and is thought to be a critical early event during checkpoint signaling in DNA-damaged cells. Eight alternatively spliced transcript variants of this gene, which encode four distinct proteins, have been reported. Two pseudogenes, located on chromosomes 7 and 13, have been identified.
References
Zhang, L., et al. EMBO J. 29(10):1726-1737(2010)
Vega, A., et al. Gynecol. Oncol. 112(1):210-214(2009)
Beretta, G.L., et al. Cancer Lett. 266(2):194-202(2008)
Zhao, M., et al. Head Neck 30(1):35-42(2008)
Rodriguez-Bravo, V., et al. Cancer Res. 66(17):8672-8679(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.